CASI Pharmaceuticals (CASIF) Enterprise Value (2021 - 2025)

CASI Pharmaceuticals has reported Enterprise Value for 5 years, with the latest figure at -$5.6 million in Q4 2025.

• For the quarter ending Q4 2025, Enterprise Value rose 58.18% year-over-year to -$5.6 million; the trailing twelve-month figure through Dec 2025 stood at -$5.6 million (up 58.18% YoY), and the FY2025 full-year result was -$5.6 million, up 58.18% from the prior year.
• Enterprise Value for Q4 2025 stood at -$5.6 million, down from -$4.7 million in the prior quarter.
• The five-year high for Enterprise Value was -$9533.0 in Q2 2024, with the low at -$19.9 billion in Q2 2023.
• Historically, Enterprise Value has averaged -$1.7 billion across 5 years, with a median of -$12.8 million in 2024.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 100.0% — and 2025, when it slumped 70601.77%.
• CASI Pharmaceuticals' Enterprise Value stood at -$25.1 million in 2021, then dropped by 4.38% to -$26.2 million in 2022, then declined by 10.98% to -$29.1 million in 2023, then surged by 53.71% to -$13.5 million in 2024, then jumped by 58.18% to -$5.6 million in 2025.
• The last three Enterprise Value figures came in at -$5.6 million (Q4 2025), -$4.7 million (Q3 2025), and -$6.7 million (Q2 2025), per Business Quant data.